Wells Fargo analyst Larry Biegelsen maintains $GE HealthCare Technologies (GEHC.US)$ with a buy rating, and maintains the target price at $95.
According to TipRanks data, the analyst has a success rate of 64.8% and a total average return of 11.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $GE HealthCare Technologies (GEHC.US)$'s main analysts recently are as follows:
GE HealthCare shares have experienced a 20% increase year-to-date and are approaching all-time highs, currently trading at a premium relative to a close peer. This premium is challenging to justify considering GE HealthCare's relatively lower growth outlook, suggesting that investor expectations may exceed even sell-side consensus. In this context, it is anticipated that GE's growth in the near to medium term may not meet expectations.
GE HealthCare has received positive news from the FDA with the approval of Flurpiridaz, a novel myocardial perfusion imaging positron emission tomography radiopharmaceutical. This product stands out because it is offered as an 'individual dose' prepared in advance, which is a departure from the current standard of on-site dose manufacturing. According to analyst research, Flurpiridaz is expected to deliver significant clinical enhancements over existing MPI radiopharmaceuticals. It is anticipated that adoption by current U.S. cardiac PET centers will be swift and that the availability of Flurpiridaz will substantially widen the reach of U.S. cardiac PET imaging.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富國集團分析師Larry Biegelsen維持$GE HealthCare Technologies (GEHC.US)$買入評級，維持目標價95美元。
根據TipRanks數據顯示，該分析師近一年總勝率為64.8%，總平均回報率為11.2%。
此外，綜合報道，$GE HealthCare Technologies (GEHC.US)$近期主要分析師觀點如下：
GE Healthcare的股價今年迄今已上漲20％，接近歷史新高，目前的交易價格相對於接近的同行溢價。考慮到通用電氣醫療保健相對較低的增長前景，這種溢價很難證明其合理性，這表明投資者的預期甚至可能超過賣方的共識。在這種情況下，預計通用電氣在短期至中期內的增長可能無法達到預期。
隨着新型心肌灌注成像正電子發射斷層掃描放射藥物Flurpiridaz的批准，GE Healthcare收到了來自美國食品藥品管理局的積極消息。該產品之所以脫穎而出，是因爲它是以事先製備的 「個人劑量」 形式提供的，這與當前的現場劑量製造標準背道而馳。根據分析師的研究，Flurpiridaz有望在現有MPI放射性藥物的基礎上提供顯著的臨床改進。預計目前的美國心臟pET中心將迅速採用該技術，Flurpiridaz的上市將大大擴大美國心臟pET成像的覆蓋範圍。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
